

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Appraisal

Fluocinolone acetonide micro-insert for treating recurrent, non-infectious uveitis
[ID1039]

Provisional stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Alimera Sciences (fluocinolone acetonide micro-insert) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Blind People • Behcets Syndrome Society • Birdshot Uveitis Society • Eyecare Trust • Fight for Sight • Macular Society • Muslim Council of Britain • National Federation of the Blind of the UK • Organisation of Blind African Caribbean's (OBAC) • Olivia's Vision • Royal National Institute of Blind People (RNIB) • SeeAbility • Sense • South Asian Health Foundation • Specialised Healthcare Alliance • Thomas Pocklington Trust <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Optometrists • British and Eire Association of Vitreoretinal Surgeons • British Geriatrics Society • British and Irish Orthoptic Society • British Ophthalmic Anaesthesia Society • College of Optometrists • Oxford Eye Foundation • Royal College of General Practitioners • Royal College of Nursing 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Uveitis Information Group (Scotland) • Wales Council for the Blind • Welsh Health Specialised Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • AbbVie (adalimumab) • Accord Healthcare (injectable methotrexate, injectable and oral mycophenolate mofetil) • Actavis UK (oral mycophenolate mofetil, oral prednisolone) • Alcon (dexamethasone eye drops and ointment) • Alimera Sciences (fluocinolone acetonide intravitreal implant) • Allergan (dexamethasone intravitreal implant, prednisolone eye drops) • Aspen Pharma Trading (oral and

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Ophthalmologists • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health & Social Care • NHS England • NHS Airedale, Wharfedale and Craven CCG • NHS Bexley CCG • Welsh Government 	<ul style="list-style-type: none"> injectable azathioprine, oral chlorambucil, oral and injectable dexamethasone) • Astellas Pharma (injectable and oral tacrolimus) • Auden McKenzie (oral dexamethasone) • Bausch & Lomb (dexamethasone eye drops, fluocinolone acetonide intravitreal implant, prednisolone eye drops) • Baxter Healthcare (injectable and oral cyclophosphamide) • Biogen Idec (infliximab biosimilar) • Chiesi (tacrolimus) • Concordia International (oral methotrexate, injectable and oral prednisolone, triamcinolone acetonide ointment) • Dexcel Pharma (oral ciclosporin) • E.R. Squibb & Sons (injectable triamcinolone acetonide) • Hameln Pharmaceuticals (injectable dexamethasone, injectable methotrexate) • Hospira UK (infliximab biosimilar, injectable dexamethasone, injectable and oral methotrexate) • Leo Laboratories (tacrolimus ointment) • Logixx Pharma (oral prednisolone) • Medac (injectable methotrexate) • Martindale Pharma (oral dexamethasone) • Merck Sharp & Dohme (infliximab) • Napp Pharmaceuticals (infliximab biosimilar) • Nordic Pharma (injectable methotrexate) • Novartis (injectable and oral ciclosporin, mycophenolic acid) • Orion Pharma (oral methotrexate) • Pfizer (oral methotrexate) • Roche Products (injectable and oral mycophenolate mofetil) • Rosemont Pharmaceuticals Ltd (oral dexamethasone, oral methotrexate) • Sandoz (azathioprine, injectable

Consultees	Commentators (no right to submit or appeal)
	<p>cyclophosphamide, oral methotrexate, oral mycophenolate mofetil, tacrolimus)</p> <ul style="list-style-type: none"> • Sanofi (dexamethasone eye drops) • Santen UK (ciclosporin eye drops) • Thea Pharmaceuticals (dexamethasone eye drops) • Wockhardt (oral mycophenolate mofetil, oralprednisolone) • Zentiva UK (oral prednisolone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Council for Prevention of Blindness • Cochrane Eyes and Vision Group • Eye Hope • Institute of Ophthalmology, University College London • International Uveitis Study Group • MRC Clinical Trials Unit • National Eye Research Centre • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.